The Effect of Extracorporeal Shock Wave Therapy on Spasticity

Sponsor
Tri-Service General Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT02221011
Collaborator
(none)
60
1
3
10
6

Study Details

Study Description

Brief Summary

The effect of traditional treatment for spasticity is barely satisfactory. The shock wave has been used to treat the spasticity with expressively response and the effect could persist for 1-3 months in different studies. However most sutdies lack the sham or control group. The purpose of this study was to assess the effect of shock wave for spasticity in wrist and hand.

Condition or Disease Intervention/Treatment Phase
  • Device: Shock wave
N/A

Detailed Description

The patients with spasticity for at least 6 months were randomized for 3 groups. Group I:

patients receive one session of shock wave per week for 3 weeks; Group II: patients receive only one session of shock wave; Group III: patients receive the sham shock wave per week for 3 weeks. The outcome measurements include Modified Asthow scale, passive range of motion, Disability Assessment Scale and Fugl-Meyer Assessment Scale (hand function and wrist control).

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
The Effect of Extracorporeal Shock Wave Therapy on Spasticity
Study Start Date :
Aug 1, 2014
Actual Primary Completion Date :
Jun 1, 2015
Actual Study Completion Date :
Jun 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: shock wave (three times)

E-SWT, Elettronica Pagani, Italy 3.5 bars 1500 beats in FCU, FCR 3 bars 4000 beats diffuse in intrinsic muscle Once a week for 3 weeks

Device: Shock wave
Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs) is conveyed by an appropriate generator to a specific target area with an energy density in the range of 0.003-0.890 mJ/mm2. Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies, calcific tendinitis of the shoulder, lateral epicondylitis, plantar fasciitis, and several tendon diseases.
Other Names:
  • E-SWT
  • Sham Comparator: Sham shock wave

    E-SWT, Elettronica Pagani, Italy Sham without energy, 1500 beats in FCU, FCR and 4000 beats diffuse in intrinsic muscle

    Device: Shock wave
    Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs) is conveyed by an appropriate generator to a specific target area with an energy density in the range of 0.003-0.890 mJ/mm2. Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies, calcific tendinitis of the shoulder, lateral epicondylitis, plantar fasciitis, and several tendon diseases.
    Other Names:
  • E-SWT
  • Experimental: Shock wave (one time)

    E-SWT, Elettronica Pagani, Italy 3.5 bars 1500 beats in FCU, FCR 3 bars 4000 beats diffuse in intrinsic muscle Only one dose

    Device: Shock wave
    Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs) is conveyed by an appropriate generator to a specific target area with an energy density in the range of 0.003-0.890 mJ/mm2. Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies, calcific tendinitis of the shoulder, lateral epicondylitis, plantar fasciitis, and several tendon diseases.
    Other Names:
  • E-SWT
  • Outcome Measures

    Primary Outcome Measures

    1. Change from baseline of spasticity on 1st, 2nd, 4th, 8th, 12th and 16th weeks after treatment. [Pre-treatment, 1st, 2nd, 4th, 8th, 12th and 16th weeks after treatment.]

      Using the modyfied Ashworth Scale to measure the spasticity before treatment and multiple time frame after treatment.

    Secondary Outcome Measures

    1. Change from baseline of range of motion on 1st, 2nd, 4th, 8th, 12th and 16th weeks after treatment. [Pre-treatment, 1st, 2nd, 4th, 8th, 12th and 16th weeks after treatment.]

      Using the digital goniometer to measure the passive range of motion before treatment and multiple time frame after treatment.

    2. Change from baseline of pain on 1st, 2nd, 4th, 8th, 12th and 16th weeks after treatment. [Pre-treatment, 1st, 2nd, 4th, 8th, 12th and 16th weeks after treatment.]

      Using the Visual analog scale (VAS) to measure the pain from spasticity scale before treatment and multiple time frame after treatment.

    3. Change from baseline of disability on 1st, 2nd, 4th, 8th, 12th and 16th weeks after treatment. [Pre-treatment, 1st, 2nd, 4th, 8th, 12th and 16th weeks after treatment.]

      Using the Disability Assessment Scale to measure the disabilty scale before treatment and multiple time frame after treatment.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    Age between 20-80 year-old Spasticity measured as Modified Asthow Scale more than 1+ point and persist at least 6 months Clear consciousness No receive Phenol injection or Botulinum toxin in past 6 months

    Exclusion Criteria:

    Cancer Joint contracture Coagulopathy Pregnancy Pacemaker Inflammation status

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Tri-Service General Hospital National Defense Medical Center Taipei Neihu Taiwan 886

    Sponsors and Collaborators

    • Tri-Service General Hospital

    Investigators

    • Principal Investigator: Yung-Tsan Wu, MD, Tri-Service General Hospital National Defense Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Yung-Tsan Wu, Attending Physician, Tri-Service General Hospital
    ClinicalTrials.gov Identifier:
    NCT02221011
    Other Study ID Numbers:
    • TSGHIRB: 2-102-05-018
    First Posted:
    Aug 20, 2014
    Last Update Posted:
    Apr 14, 2016
    Last Verified:
    Apr 1, 2016
    Keywords provided by Yung-Tsan Wu, Attending Physician, Tri-Service General Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 14, 2016